Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis
- 18 August 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (3) , 974-987
Abstract
Objective Triple-negative breast cancer (TNBC) presents a clinical challenge as an aggressive tumor, correlated with unfavorable prognosis. Tumor-infiltrating lymphocytes (TILs) have garnered interest as a potential prognostic biomarker. However, the disparity in outcomes between varying TILs rates remains inadequately explored. Methods PubMed, Scopus, Web of Science, and Cochrane databases were searched for studies about the prognostic value of TILs in patients with TNBC receiving neoadjuvant chemotherapy. The hazard ratios (HRs) or odds ratios (ORs) were computed for binary endpoints, with 95% confidence intervals (CIs). Results Twenty-nine studies were included, involving a population of six thousand one hundred sixty-one (80.41%) with TNBC. The cut-off TILs value ranged from 10 to 60%, with 50% being the most related value. Compared with the low-TIL expression group, the disease-free survival (DFS) (HR 0.71; 95% CI 0.61–0.82; p < 0.00001) and overall survival (OS) (HR 0.76; 95% CI 0.63–0.90; p = 0.002) rates showed significant improvement with higher TIL infiltrations. In the subgroup analyses of the lymphocyte subtypes CD4 + and CD8 + , there was statistical significance favoring higher TILs rates in both subtypes, each associated with improved DFS (HR 0.48; 95% CI 0.33–0.71; p = 0.0002) and OS (HR 0.53; 95% CI 0.36–0.78; p = 0.001), regardless of which cell subtype was predominantly infiltrated. The complete pathological response analysis showed better rates for the higher TIL group than the control for both the TIL (OR 1.29; 95% CI 1.13–1.48; p = 0.0003) and Ki-67 (OR 2.74; 95% CI 2.01–3.73; p < 0.00001) analyses. Conclusion Higher expressions of TILs in patients with TNBC were associated with improved significantly DFS, OS, and pCR outcomes.Keywords
This publication has 88 references indexed in Scilit:
- Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trialsEuropean Journal of Clinical Pharmacology, 2024
- CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancerVirchows Archiv, 2019
- Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapyBreast Cancer Research and Treatment, 2019
- Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trialInternational Journal of Cancer, 2019
- An overview of triple-negative breast cancerArchives of Gynecology and Obstetrics, 2015
- DJ-1 protein expression as a predictor of pathological complete remission after neoadjuvant chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2013
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewBreast Cancer Research and Treatment, 2011
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Research and Treatment, 2011
- Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patientsCancer Chemotherapy and Pharmacology, 2010
- Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patientsCancer, 2007